ArticleJournal of neurovirology2014

Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

Lishomwa C Ndhlovu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.